Fenofibrate may reduce CVD in patients with DM, dyslipidemia

January 4, 2017

(HealthDay)—Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia, according to a study published online Dec. 28 in JAMA Cardiology.

Marshal B. Elam, M.D., Ph.D., from the Memphis Veterans Affairs Medical Center and University of Tennessee Health Sciences Center, and colleagues examined whether fenofibrate reduces CVD risk in statin-treated patients with type 2 . A total of 4,644 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study participants were followed for an additional five years, for a total of 9.7 years.

The researchers found that following completion of ACCORD, only 4.3 percent of study participants continued fenofibrate treatment. Among participants originally randomized to fenofibrate or placebo, and triglyceride values rapidly equalized. During 9.7 years of follow-up, the hazard ratio for the primary study outcome (composite of fatal and nonfatal myocardial infarction and stroke) among participants originally randomized to fenofibrate versus placebo (hazard ratio, 0.93; 95 percent confidence interval, 0.83 to 1.05; P = 0.25) was comparable with that originally seen in ACCORD (hazard ratio, 0.92; 95 percent confidence interval, 0.79 to 1.08; P = 0.32). For with dyslipidemia, fenofibrate therapy effectively reduced CVD (hazard ratio, 0.73; 95 percent confidence interval, 0.56 to 0.95).

"The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; several pharmaceutical companies provided study medications, equipment, and supplies during ACCORD.

Explore further: Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

More information: Full Text (subscription or payment may be required)

Related Stories

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

December 28, 2016
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated ...

Rate of CVD mortality, MI, stroke down for patients on semaglutide

September 17, 2016
(HealthDay)—Semaglutide is noninferior to placebo for patients with type 2 diabetes at high cardiovascular risk, according to a study published online Sept. 16 in the New England Journal of Medicine. The research was published ...

Two variants ID cardiovascular effect of intensive glycemic Tx

August 24, 2016
(HealthDay)—Two genetic variants predict the cardiovascular effect of intensive glycemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, according to research published online Aug. 15 in ...

Testosterone and fenofibrate yields strongest effect on cardio risks

June 17, 2015
(HealthDay)—A combination of testosterone and fenofibrate may offer men with high cholesterol and late-onset hypogonadism the most cardiometabolic benefit, according to a study published online May 29 in Cardiovascular ...

PPI cuts risk of warfarin-related upper GI bleeding

December 23, 2016
(HealthDay)—For patients beginning warfarin therapy, proton pump inhibitor (PPI) co-therapy is associated with reduced risk of upper gastrointestinal bleeding, according to a study published in the December issue of Gastroenterology.

AHA: Ticagrelor not shown to be superior to clopidogrel in PAD

November 16, 2016
(HealthDay)—Ticagrelor is not superior to clopidogrel for reduction of cardiovascular events in patients with peripheral artery disease, according to a study published online Nov. 13 in the New England Journal of Medicine ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.